MedTrace Logo

Treatment of Tendon Injury Using Mesenchymal Stem Cells

NCT01856140 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-03-18

Study results available
· View outcomes & findings →

Summary

Main purpose of this study is to evaluate efficacy and safety of allogenic adipose-derived mesenchymal stem cells(ALLO-ASC) in treatment of tendon injury. ALLO-ASC will be administrated to the patients with lateral epicondylitis by ultrasonographic guided injection.

Conditions

  • Lateral Epicondylitis

Interventions

BIOLOGICAL

ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection

Sponsors & Collaborators

  • Medical Research Collaborating Center, Seoul, Korea

    collaborator OTHER

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Sun Gun Chung, MD, PhD · Seoul National University College of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2016-07-31
Completion
2018-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01856140 on ClinicalTrials.gov